NASDAQ:VIR Vir Biotechnology (VIR) Stock Price, News & Analysis $5.03 -0.04 (-0.79%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$5.17 +0.14 (+2.86%) As of 08/1/2025 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vir Biotechnology Stock (NASDAQ:VIR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vir Biotechnology alerts:Sign Up Key Stats Today's Range$4.89▼$5.0550-Day Range$4.50▼$5.9352-Week Range$4.32▼$14.45Volume809,884 shsAverage Volume1.08 million shsMarket Capitalization$695.35 millionP/E RatioN/ADividend YieldN/APrice Target$30.25Consensus RatingModerate Buy Company Overview Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. Read More Vir Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreVIR MarketRank™: Vir Biotechnology scored higher than 57% of companies evaluated by MarketBeat, and ranked 424th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingVir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVir Biotechnology has only been the subject of 2 research reports in the past 90 days.Read more about Vir Biotechnology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vir Biotechnology are expected to grow in the coming year, from ($3.92) to ($3.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vir Biotechnology's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.67% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 50.73%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.67% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 50.73%, indicating that investor sentiment is decreasing significantly. News and Social Media2.3 / 5News Sentiment0.19 News SentimentVir Biotechnology has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Vir Biotechnology this week, compared to 5 articles on an average week.Search Interest10 people have searched for VIR on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $185,150.00 in company stock.Percentage Held by Insiders16.00% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vir Biotechnology's insider trading history. Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address VIR Stock News HeadlinesInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 3,586 Shares of StockJuly 18, 2025 | insidertrades.comVicki L. Sato Sells 22,000 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) StockJuly 3, 2025 | insidertrades.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 3 at 2:00 AM | The Oxford Club (Ad)Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis DeltaJuly 31 at 8:05 AM | businesswire.comFirst subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525July 25, 2025 | finance.yahoo.comVir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid TumorsJuly 24, 2025 | businesswire.comVir Biotechnology: Hep B And Cancer Projects March OnJuly 23, 2025 | seekingalpha.comVir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025July 22, 2025 | businesswire.comSee More Headlines VIR Stock Analysis - Frequently Asked Questions How have VIR shares performed this year? Vir Biotechnology's stock was trading at $7.34 at the start of the year. Since then, VIR shares have decreased by 31.5% and is now trading at $5.03. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) announced its quarterly earnings data on Wednesday, May, 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by $0.05. The company's quarterly revenue was down 94.6% on a year-over-year basis. Read the conference call transcript. When did Vir Biotechnology IPO? Vir Biotechnology (VIR) raised $149 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO. Who are Vir Biotechnology's major shareholders? Top institutional shareholders of Vir Biotechnology include Aberdeen Group plc (0.73%), Nordea Investment Management AB (0.51%), Clarius Group LLC (0.45%) and Allianz Asset Management GmbH (0.24%). Insiders that own company stock include Endurance (Cayman) Ltd Svf, Vicki L Sato, Backer Marianne De, George A Scangos, Phillip Pang, Howard Horn, Ann M Hanly, Steven J Rice, Mark Eisner, Sung Lee, Verneuil Vanina De, Brent Sabatini, Janet Napolitano, Saira Ramasastry and Charles Elliott Sigal. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vir Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vir Biotechnology investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Home Depot (HD), Moderna (MRNA) and Visa (V). Company Calendar Last Earnings5/07/2025Today8/03/2025Next Earnings (Confirmed)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VIR CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees580Year FoundedN/APrice Target and Rating Average Price Target for Vir Biotechnology$30.25 High Price Target$110.00 Low Price Target$12.00 Potential Upside/Downside+501.4%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($4.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$521.96 million Net Margins-2,769.04% Pretax Margin-2,775.77% Return on Equity-47.46% Return on Assets-39.33% Debt Debt-to-Equity RatioN/A Current Ratio6.79 Quick Ratio6.79 Sales & Book Value Annual Sales$74.21 million Price / Sales9.37 Cash FlowN/A Price / Cash FlowN/A Book Value$8.35 per share Price / Book0.60Miscellaneous Outstanding Shares138,240,000Free Float116,120,000Market Cap$695.35 million OptionableOptionable Beta1.18 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:VIR) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.